2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Lactate Dehydrogenase

Lactate Dehydrogenase

LDH

Lactate Dehydrogenase

Related Products

PDF 0.33 MB

Lactate Dehydrogenase (LDH) is an enzyme that catalyzes the conversion of pyruvate, the end product of glycolysis, into lactate (and vice versa) with concomitant interconversion of NADH and NAD+. LDH is comprised of two major subunits, LDH-A and LDH-B, which can assemble into five different isoenzymes (LDH1, LDH2, LDH3, LDH4, and LDH5).

LDH-A is also known as the M subunit as it is predominantly found in skeletal muscle, and LDH-B is also known as the H subunit as it is predominantly found in the heart. LDH-A is a vital metabolic enzyme that is associated with cancer development, invasion, and metastasis. LDH-A is also the key player of the Warburg effect. LDH-A has been reported to correlate with clinicopathologic characteristics and survival outcome of multiple cancers. The inhibition of LDH-A has an anti-proliferative effect on primary breast tumors. LDH-B is a crucial glycolytic enzyme that catalyses conversion of lactate and NAD+ to pyruvate, NADH and H+. LDHB plays an important role in autophagy in cancer cells.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-100681R
    GSK2837808A (Standard)
    		Inhibitor
    GSK2837808A (Standard) is the analytical standard of GSK2837808A (HY-100681). This product is intended for research and analytical applications. GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 2.6 and 43 nM for hLDHA and hLDHB, respectively.
    GSK2837808A (Standard)
  • HY-180992
    Dual GO/LDHA-IN-1
    		Inhibitor
    Dual GO/LDHA-IN-1 is an orally available dual inhibitor targeting glycolate oxidase (GO) and lactate dehydrogenase A (LDHA), with Ki values of 390 nM and 40 nM, respectively. Dual GO/LDHA-IN-1 reduces hepatic LDHA levels, urinary oxalate excretion, and renal calcium-oxalate crystal deposition. Dual GO/LDHA-IN-1 is applicable for research on primary hyperoxaluria type 1.
    Dual GO/LDHA-IN-1
  • HY-W040073R
    Nifurtimox (Standard)
    		Inhibitor
    Nifurtimox (Standard) is the analytical standard of Nifurtimox. This product is intended for research and analytical applications. Nifurtimox, an antiprotozoal agent, which is generally used for the treatment of infections with Trypanosoma cruzi, has been used in the therapy of neuroblastoma. Nifurtimox affects enzyme activity of lactate dehydrogenase (LDH).
    Nifurtimox (Standard)
  • HY-171944
    6-O-Oleoyltrehalose
    6-O-Oleoyltrehalose is a derivative of trehalose. 6-O-Oleoyltrehalose has biodegradable and low surface tension reduction ability. 6-O-Oleoyltrehalose preserves Lactate dehydrogenase (LDH) activity during freeze/thaw cycles. 6-O-Oleoyltrehalose can be used for stabilizer research.
    6-O-Oleoyltrehalose
  • HY-N6948R
    Linalyl acetate (Standard)
    		Inhibitor
    Linalyl acetate (Standard) is the analytical standard of Linalyl acetate. This product is intended for research and analytical applications. Linalyl acetate is the principal components of many plant essential oils. Linalyl acetate exhibits anti-anxiety, anti-inflammatory, anti-diabetic, anti-stress, and cardiovascular-regulatory effects. Linalyl acetate is orally active.
    Linalyl acetate (Standard)
  • HY-100742R
    GNE-140 racemate (Standard)
    		Inhibitor
    GNE-140 (racemate) (Standard) is the analytical standard of GNE-140 (racemate) (HY-100742). This product is intended for research and analytical applications. GNE-140 racemate is a racemate mixture of (R)-GNE-140 and (S)-GNE-140. GNE-140 racemate is a potent lactate dehydrogenase A (LDHA) inhibitor.
    GNE-140 racemate (Standard)
  • HY-180110
    Antiparasitic agent-32
    		Inhibitor
    Antiparasitic agent-32 (compound M9), a Piperaquine (HY-B1896) analog, is a potent P. falciparum lactate dehydrogenase (Pf LDH)-targeting antiparasitic agent (Pf3D7 IC50 = 0.40 μM). Antiparasitic agent-32 exhibits significant activity against both Pf asexual and gametocyte stages. Antiparasitic agent-32 exerts antiplasmodial activity through stable and specific noncovalent interactions at the NADH-binding site. Antiparasitic agent-32 can be used for malaria research.
    Antiparasitic agent-32
  • HY-110119
    Galloflavin potassium
    		Inhibitor
    Galloflavin potassium is a novel lactate dehydrogenase inhibitor that can be used for the research of cancer. Galloflavin inhibits aerobic glycolysis in PLC/PRF/5 cells and triggers cell death via apoptosis.
    Galloflavin potassium
  • HY-14257
    BMS-191095 hydrochloride
    		Inhibitor
    BMS-191095 hydrochloride is a mitochondrial KATP channel opener. BMS-191095 hydrochloride can protect the myocardium without causing vasodilation or affecting electrophysiology, by prolonging the contraction time during ischemia, improving contractile function after reperfusion, and reducing lactate dehydrogenase (LDHM) release, thereby exerting its cardioprotective effects.
    BMS-191095 hydrochloride
  • HY-137162
    Dotarizine
    		Inhibitor
    Dotarizine is a novel Piperazine (HY-B0912) derivative and antimigraine agent. Dotarizine exhibits Ca2+ channel blocking properties. Dotarizine decreases the release of lactate dehydrogenase. Dotarizine shows 5-HT receptor blocking effect.
    Dotarizine
Cat. No. Product Name / Synonyms Application Reactivity